GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (WBO:BMYS) » Definitions » Debt-to-Equity

Bristol-Myers Squibb Co (WBO:BMYS) Debt-to-Equity : 3.00 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bristol-Myers Squibb Co Debt-to-Equity?

Bristol-Myers Squibb Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1,120 Mil. Bristol-Myers Squibb Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €45,191 Mil. Bristol-Myers Squibb Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €15,445 Mil. Bristol-Myers Squibb Co's debt to equity for the quarter that ended in Sep. 2024 was 3.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bristol-Myers Squibb Co's Debt-to-Equity or its related term are showing as below:

WBO:BMYS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.4   Med: 0.94   Max: 3.48
Current: 3

During the past 13 years, the highest Debt-to-Equity Ratio of Bristol-Myers Squibb Co was 3.48. The lowest was 0.40. And the median was 0.94.

WBO:BMYS's Debt-to-Equity is ranked worse than
95.65% of 827 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs WBO:BMYS: 3.00

Bristol-Myers Squibb Co Debt-to-Equity Historical Data

The historical data trend for Bristol-Myers Squibb Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Debt-to-Equity Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 1.37 1.27 1.31 1.41

Bristol-Myers Squibb Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.41 3.48 3.17 3.00

Competitive Comparison of Bristol-Myers Squibb Co's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Debt-to-Equity falls into.



Bristol-Myers Squibb Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bristol-Myers Squibb Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Bristol-Myers Squibb Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (WBO:BMYS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Bristol-Myers Squibb Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Co Headlines

No Headlines